Insulin Resistance and Hyperinsulinemia in Patients with Chronic Liver Disease and Hepatocellular Carcinoma

2009 ◽  
Vol 2 ◽  
pp. CMED.S3116 ◽  
Author(s):  
Valter Donadon ◽  
Massimiliano Balbi ◽  
Antonio Perciaccante ◽  
Pietro Casarin ◽  
Giorgio Zanette
Keyword(s):  
Hepatocellular Carcinoma ◽  
Insulin Resistance ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Healthy Subjects ◽  
Chronic Liver ◽  
Metabolic Factors ◽  
Mean Values ◽  
The Mean

Objectives To investigate the role of insulin resistance (IR) and insulin plasma levels (IRI) in patients with chronic liver disease (CLD) and hepatocellular carcinoma (HCC). Methods We recruited the following patients: 125 with HCC, 128 with liver cirrhosis (LC) and 133 with chronic hepatitis C (CHC). IR was assessed by the HOMA-IR method. To define IR and hyperinsulinemia we selected as a cut-off level, the value of the 80th percentile for HOMA-IR (2.72) and IRI (11.18) in 113 healthy subjects. Results The mean levels of HOMA-IR and IRI increase progressively among CHC (2.7 ± 2.9 and 11.5 ± 10.5, respectively), LC (5.4 ± 4.5 and 17.6 ± 11.2) and HCC (6.4 ± 9.8 and 18.2 ± 18.8). In the upper quintiles for HOMA-IR and IRI, the frequency of patients in the LC and HCC groups was twice as much in CHC cases. HCC with DM2 have the greatest percentage above the 80th percentile of HOMA-IR, their quintiles distribution is inverted and HOMA-IR mean values are significantly higher in comparison with HCC without DM2 cases. Discussion Our study shows that the association between IR and CLD begins in the early stages of liver fibrosis. DM2 increases HOMA-IR and IRI mean levels in HCC patients and these metabolic factors could play a major role in the link between diabetes mellitus and hepatocarcinoma.

scholarly journals Sequential Occurrence of Hepatocellular Carcinoma Following Waldenstroem's Macroglobulinemia: The Pathogenetic Role of Chronic Liver Disease.

1996 ◽  
Vol 35 (5) ◽  
pp. 416-418 ◽  
Author(s):  
Tohru IZUMI ◽  
Ryuhei SASAKI ◽  
Saburo TSUNODA ◽  
Makio HATAKEYAMA ◽  
Hirotaka KOYAMA ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Pathogenetic Role

P606 THE ROLE OF TGF-β2 IN CHRONIC LIVER DISEASE (CLD) AND HEPATOCELLULAR CARCINOMA (HCC)

2014 ◽  
Vol 60 (1) ◽  
pp. S271
Author(s):  
A. Dropmann ◽  
T. Dediulia ◽  
S. Weber ◽  
K. Abshagen ◽  
M. Wieland ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver

Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance

2021 ◽  
Vol 29 (3) ◽  
pp. 279-290
Author(s):  
Hailey H. Choi ◽  
Shuchi K. Rodgers ◽  
Aman Khurana ◽  
Leslie W. Nelson ◽  
Aya Kamaya
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Hepatocellular Carcinoma Surveillance

Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers

2010 ◽  
Vol 25 (1) ◽  
pp. 129-137 ◽  
Author(s):  
Pisit Tangkijvanich ◽  
Theerawut Chanmee ◽  
Sanpoj Komtong ◽  
Varocha Mahachai ◽  
Naruemon Wisedopas ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Liver Cancers ◽  
Diagnostic Role

scholarly journals The impact of endotrophin on the progression of chronic liver disease

2020 ◽  
Vol 52 (10) ◽  
pp. 1766-1776
Author(s):  
Min Kim ◽  
Changhu Lee ◽  
Dae Yun Seo ◽  
Hyojung Lee ◽  
Jay D. Horton ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Insulin Resistance ◽  
Liver Disease ◽  
Liver Cancer ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Hepatic Inflammation ◽  
Fibrotic Liver ◽  
Alcoholic Fatty Liver ◽  
The Impact

Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and can lead to multiple complications, including non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. The fibrotic liver is characterized by the pathological accumulation of extracellular matrix (ECM) proteins. Type VI collagen alpha3 (Col6a3) is a biomarker of hepatic fibrosis, and its cleaved form, endotrophin (ETP), plays a critical role in adipose tissue dysfunction, insulin resistance, and breast cancer development. Here, we studied the effects of the Col6a3-derived peptide ETP on the progression of chronic liver diseases, such as NASH and liver cancer. We used a doxycycline (Dox)-inducible liver-specific ETP-overexpressing mouse model on a NAFLD-prone (liver-specific SREBP1a transgenic) background. For this, we evaluated the consequences of local ETP expression in the liver and its effect on hepatic inflammation, fibrosis, and insulin resistance. Accumulation of ETP in the liver induced hepatic inflammation and the development of fibrosis with associated insulin resistance. Surprisingly, ETP overexpression also led to the emergence of liver cancer within 10 months in the SREBP1a transgenic background. Our data revealed that ETP can act as a “second hit” during the progression of NAFLD and can play an important role in the development of NASH and hepatocellular carcinoma (HCC). These observations firmly link elevated levels of ETP to chronic liver disease.

Functional role of CCL5/RANTES for hepatocellular carcinoma progression during chronic liver disease

2017 ◽  
Vol 66 (1) ◽  
pp. S227-S228 ◽  
Author(s):  
A. Mohs ◽  
N. Kuttkat ◽  
J. Reißing ◽  
H.W. Zimmermann ◽  
R. Sonntag ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Functional Role ◽  
Chronic Liver

Reversal of extrahepatic membrane cholesterol deposition in patients with chronic liver diseases by S-adenosyl-l-methionine

1992 ◽  
Vol 83 (3) ◽  
pp. 353-356 ◽  
Author(s):  
Samina Rafique ◽  
Marianna Guardascione ◽  
Elsir Osman ◽  
Andrew K. Burroughs ◽  
James S. Owen
Keyword(s):  
Liver Disease ◽  
Oral Administration ◽  
Chronic Liver Disease ◽  
Therapeutic Potential ◽  
Plasma Cholesterol ◽  
Chronic Liver ◽  
Erythrocyte Membranes ◽  
Molar Ratio ◽  
Mean Values ◽  
The Mean

1. S-Adenosyl-l-methionine is reported to improve serum liver function tests in chronic liver disease. Because liver disease is complicated by cholesterol deposition in hepatic and extrahepatic membranes, we have assessed whether oral administration of S-adenosyl-l-methionine to patients with hepatic disease can reverse the cholesterol enrichment of their erythrocytes. 2. The mean erythrocyte cholesterol-to-phospholipid molar ratio in 13 jaundiced patients was reduced 2 weeks after oral administration of S-adenosyl-l-methionine (from 0.874 ± 0.112 to 0.844 ± 0.102, P<0.05) with 10 of the patients (77%) showing a decrease. By contrast, only four of 11 untreated patients (36%) had a reduced erythrocyte cholesterol-to-phospholipid molar ratio after 2 weeks and the mean values did not differ. 3. The plasma and erythrocyte cholesterol-to-phospholipid molar ratios remained closely correlated (r = 0.77, P<0.01) before and after treatment, suggesting that S-adenosyl-l-methionine had not acted directly on the cells but rather had improved their lipoprotein milieu. Further support for this concept was provided by following one patient, who initially failed to respond, during an additional 3 weeks of S-adenosyl-l-methionine administration. The plasma cholesterol-to-phospholipid molar ratio fell steadily from week 1 to week 5 and was accompanied by a progressive decrease in the erythrocyte cholesterol-to-phospholipid molar ratio. Moreover, the initially suppressed acetylcholinesterase activity of the erythrocyte membranes returned towards normal during this period. 4. This preliminary study is the first evidence in jaundiced patients that a drug can help to reverse the deposition of cholesterol in an extrahepatic membrane. It merits, therefore, placebo-controlled, crossover investigations into the therapeutic potential of S-adenosyl-l-methionine in chronic liver disease.

Sign in / Sign up

Export Citation Format

Share Document